RA Capital Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q3
Sell
-3,126,131
Closed -$25.3M 71
2020
Q2
$25.3M Buy
+3,126,131
New +$27.6M 0.49% 38

Other funds holding AVDL

RA Capital Management's AVDL Position: Q3 2020 in Review

RA Capital Management sold out of Avadel Pharmaceuticals (AVDL) in Q3 2020, closing a stake of 3,126,131 shares — an estimated $25.3M sold.

RA Capital Management first reported a position in AVDL in Q2 2020 and held it in 1 quarter. The position peaked at $25.3M in Q2 2020. 79 funds tracked by Wall St. Rank hold AVDL as of Q3 2020.

  • RA Capital Management reported no remaining Avadel Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • RA Capital Management sold 3,126,131 Avadel Pharmaceuticals shares in Q3 2020, an estimated $25.3M.
  • RA Capital Management first reported a position in Avadel Pharmaceuticals in Q2 2020 and held it in 1 quarter.
  • RA Capital Management's Avadel Pharmaceuticals position peaked at $25.3M in Q2 2020.
  • 79 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2020.

Based on RA Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.